Figure 4

In vivo evaluation of the PLGA-rSEA vaccine protection. (A) Percent survival after infection; (B) In vivo growth of S. aureus in the liver after challenge; (C) In vivo growth of S. aureus in the spleen after challenge. BALB/c mice were vaccinated with PLGA-rSEA and then challenged i.p. with 10⁸ CFU of S. aureus for bacterial clearance analysis (A and B) and 10⁹ CFU lethal doses of S. aureus for percent survival analysis (C) (*, P < 0.05; **, P < 0.01, compared with the PBS group).